+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients



Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients



British Journal of Rheumatology 36(3): 345-352



The objective was to compare the safety and efficacy of methotrexate (MTX) and gold sodium thiomalate (GSTM) in patients with early erosive rheumatoid arthritis (RA). A total of 174 patients with active early erosive RA without deformities were enrolled in a 12 month, two-centre double-blind randomized trial. They received a weekly i.m. dose of 15 mg MTX (n = 87) or 50 mg GSTM (n = 87), respectively. Clinical and laboratory evaluations were carried out every 3 months in all patients, including the withdrawals. Ten patients (11.5%) in the MTX group and 21 patients (24.1%) in the GSTM group achieved a clinical remission of the disease [no swollen joints, erythrocyte sedimentation rate (ESR) < 20 mm, no steroids] within the study period (P < 0.05). An at least marked improvement (> 50% reduction of the number of swollen and tender joints and the ESR) was assessed in 59/87 (68%) and 66/87 (76%) patients treated with MTX or GSTM, respectively (P > 0.05). Significantly more patients in the GSTM group were withdrawn due to toxicity (six MTX/32 GSTM). A total of 126 patients (73 on MTX and 53 on GSTM) completed 12 months on their original medication. In the completers, a significant improvement of > 50% compared to baseline was noted in all six clinical variables [morning stiffness, joint count of swollen and tender joints, Lansbury index, grip strength and activities of daily living (ADL) score], the ESR and the C-reactive protein, without intergroup differences. The number of patients taking prednisone was reduced from 21 to 7% in the MTX group and from 15 to 4% in the GSTM group. While significantly more patients achieved a clinical remission with GSTM treatment, tolerability was significantly better with MTX.

(PDF emailed within 0-6 h: $19.90)

Accession: 008358667

Download citation: RISBibTeXText

PMID: 9133967

DOI: 10.1093/rheumatology/36.3.345


Related references

A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. Journal of Rheumatology 18(3): 328-333, 1991

Interim report on 102 patients after two years in a double blind comparison of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. Zeitschrift fuer Rheumatologie 51(4): 163-171, 1992

One year randomized double blind study of methotrexate mtx and gold sodium thiomalate gst in early erosive rheumatoid arthritis ra. Arthritis & Rheumatism 33(9 SUPPL): S39, 1990

A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Rheumatology 37(10): 1060-1068, 1998

Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. British Journal of Rheumatology 37(11): 1220-1226, 1998

A 36 months comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. British Journal of Rheumatology 37(10): 1060-1068, 1998

Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology 41(2): 196-204, 2002

A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months. Seminars in Arthritis and Rheumatism 21(2 Suppl 1): 13-20, 1991

One year data in blind randomised trial methotrexate mtx and gold sodium thiomalate gst in active early rheumatoid arthritis ra. Arthritis & Rheumatism 34(9 SUPPL): S36, 1991

Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis--a randomized, double blind 26-week trial. Journal of Rheumatology 16(3): 302-306, 1989

A blinded randomized trial of methotrexate mtx and gold sodium thiomalate gst in early erosive rheumatoid arthritis ra. Arthritis & Rheumatism 32(4 SUPPL): S43, 1989

Gold sodium thiomalate gstm compared to methotrexate mtx therapy in rheumatoid arthritis ra a 24 week double blind study preliminary results. Clinical & Investigative Medicine 10(4 SUPPL B): B124, 1987

A Multicentre Double-Blind Comparison Of Auranofin, Intramuscular Gold Thiomalate And Placebo In Patients With Psoriatic Arthritis. Rheumatology 29(4): 280-283, 1990

A multicenter double blind comparison of auranofin intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. British Journal of Rheumatology 29(4): 280-283, 1990

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636): 375-382, 2008